Issn Print: 1522-8517
Publication Date: 2017/04/06
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T. Batchelor; Elizabeth R. Gerstner; Xiaobu Ye; Serena Desideri; Daniel G. Duda; David Peereboom; Glenn J. Lesser; Sajeel Chowdhary; Patrick Y. Wen; Stuart Grossman; Jeffrey G. Supko
Author Information: Departments of Neurology (T.T.B., E.R.G.) and Radiation Oncology (T.T.B., D.G.D.), Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (T.T.B., E.R.G., J.G.S.); Johns Hopkins University School of Medicine, Baltimore, Maryland (X.Y., S.D., S.G.); Cleveland Clinic, Cleveland, Ohio (D.P.); Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina (G.J.L.); Moffitt Cancer Center, Tampa, Florida (S.C.); Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.)
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.